Anti-CD (eg, daratumumab) as part of a combination regimen or as a monotherapy Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible.

For Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd) and Daratumumab + bortezomib + melphalan + prednisone + dexamethasone (D-VMP) regimen: newly diagnosed myeloma

Any prior therapy with daratumumab

Received daratumumab or other anti-CD therapies previously

Subject has received daratumumab or other anti-CD therapies previously

SY- and daratumumab combination only - Prior or concurrent exposure to daratumumab or other CD therapies.

SY- and daratumumab combination only - Subject has either of the following:

Prior treatment with anti-CD therapy including daratumumab (Cohorts D, D, E, F)

Have received prior ixazomib at any time or daratumumab or other anti-CD therapies, except as part of initial therapy if this was stopped to move on to SCT and the participants did not progress on anti-CD treatment.

Prior daratumumab or other anti-CD antibody

Cancer chemotherapy within  weeks prior to start of daratumumab treatment (steroid or hydroxyurea can be used up to  hours prior to first daratumumab infusion for control of high white cell counts)

Has received prior treatment with daratumumab or other anti-CD therapies previously

Previously received daratumumab or other anti-CD therapies

Participant has received daratumumab or other anti-cluster of differentiation  (anti-CD) therapies previously

Has received daratumumab or other anti-CD therapies previously

Anti-cluster of differentiation(CD) therapy, including daratumumab

Has received any of the following therapies: daratumumab or other anti-CD therapies

Disease progression on daratumumab

Previous therapy with daratumumab or other anti-CD monoclonal antibodies.

Daratumumab or other anti-CD therapies

Patients must have received >=  daratumumab infusions and be scheduled to receive another dose

Prior exposure to daratumumab or prior exposure to other anti-Cluster of Differentiation  (anti-CD) therapies

Daratumumab or other anti CD antibody treatment within  months prior to study enrollment